trending Market Intelligence /marketintelligence/en/news-insights/trending/lbq_mukwopppxiekafp-1a2 content esgSubNav
In This List

Audentes muscle disorder treatment gets priority tag in EU

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Audentes muscle disorder treatment gets priority tag in EU

Audentes Therapeutics Inc. said the European Medicines Agency granted priority medicines, or Prime, designation to its drug candidate AT132.

AT132 is being developed to treat X-linked myotubular myopathy, a rare inherited disease characterized by extreme muscle weakness, respiratory failure and early death. XLMTM occurs almost exclusively in newborn males, with an estimated 50% mortality rate by 18 months of age.

The EMA's Prime designation helps optimize development plans and expedite the evaluation of certain drugs, so they reach patients as soon as possible.

San Francisco-based Audentes said AT132 previously received orphan drug status from the EMA. The U.S. Food and Drug Administration already granted AT132 rare pediatric disease, fast track and orphan drug designations.